Sound View Wealth Advisors Group LLC Sells 620 Shares of Sanofi (NASDAQ:SNY)

Sound View Wealth Advisors Group LLC trimmed its position in Sanofi (NASDAQ:SNY) by 10.0% in the first quarter, according to its most recent filing with the SEC. The institutional investor owned 5,577 shares of the company’s stock after selling 620 shares during the period. Sound View Wealth Advisors Group LLC’s holdings in Sanofi were worth $309,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Mirae Asset Global Investments Co. Ltd. grew its position in shares of Sanofi by 124.0% during the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 24,131 shares of the company’s stock valued at $1,344,000 after acquiring an additional 13,358 shares during the period. Axxcess Wealth Management LLC grew its position in shares of Sanofi by 130.5% during the 1st quarter. Axxcess Wealth Management LLC now owns 10,234 shares of the company’s stock valued at $568,000 after acquiring an additional 5,794 shares during the period. Ballentine Partners LLC grew its position in shares of Sanofi by 68.7% during the 1st quarter. Ballentine Partners LLC now owns 26,063 shares of the company’s stock valued at $1,445,000 after acquiring an additional 10,617 shares during the period. Sowell Financial Services LLC bought a new position in shares of Sanofi during the 1st quarter valued at approximately $328,000. Finally, Farther Finance Advisors LLC grew its position in shares of Sanofi by 66.2% during the 1st quarter. Farther Finance Advisors LLC now owns 6,215 shares of the company’s stock valued at $338,000 after acquiring an additional 2,476 shares during the period. 14.04% of the stock is owned by institutional investors.

Sanofi Stock Performance

Shares of SNY stock opened at $46.75 on Friday. The stock has a market capitalization of $114.65 billion, a P/E ratio of 11.24, a PEG ratio of 1.05 and a beta of 0.48. The company has a current ratio of 1.37, a quick ratio of 0.69 and a debt-to-equity ratio of 0.16. The firm’s 50 day moving average is $49.10 and its 200 day moving average is $52.08. Sanofi has a 12 month low of $44.73 and a 12 month high of $60.12.

Sanofi (NASDAQ:SNY) last posted its earnings results on Thursday, July 31st. The company reported $0.90 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.96 by ($0.06). Sanofi had a return on equity of 18.85% and a net margin of 21.47%. The firm had revenue of $11.34 billion during the quarter, compared to analysts’ expectations of $9.91 billion. During the same quarter in the prior year, the company earned $1.73 earnings per share. The business’s revenue for the quarter was down 7.0% compared to the same quarter last year. On average, sell-side analysts anticipate that Sanofi will post 4.36 earnings per share for the current year.

Wall Street Analyst Weigh In

SNY has been the subject of a number of research reports. Wall Street Zen raised shares of Sanofi from a “hold” rating to a “buy” rating in a research report on Saturday. BNP Paribas initiated coverage on shares of Sanofi in a research report on Tuesday, April 15th. They set an “outperform” rating and a $65.00 target price for the company. Guggenheim reissued a “buy” rating on shares of Sanofi in a research report on Tuesday, June 3rd. Barclays reissued an “overweight” rating on shares of Sanofi in a research report on Wednesday, July 2nd. Finally, Morgan Stanley set a $56.00 price target on shares of Sanofi in a research note on Monday, June 2nd. Two research analysts have rated the stock with a hold rating, four have assigned a buy rating and three have assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $62.00.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.